Since the malignant B cells in CLL require B cell receptor (BCR) signaling for survival (5), targeting the BCR signaling pathway using small-molecule inhibitors, such as Ibrutinib (targeting Bruton’s tyrosine kinase) and Idelalisib (targeting phosphatidylinositol 3-kinase δ), has proven successful in the management of CLL (6, 7). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.